Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes.
暂无分享，去创建一个
A. Letai | E. Cesarman | A. Melnick | R. Puri | Matt Teater | S. Mathew | Hanna Scholze | L. Giulino-Roth | S. Parvin | Vicenta Trujillo-Alonso | Shivem B. Shah | Raymond Reynolds | S. Butler | H. Ueno | Ankur Singh | Regan E. Stephenson | Herman van Besien | Destini Gibbs-Curtis | L. Giulino‐Roth